Latest News
Early study suggests a new, injectable gel may greatly reduce chronic low back pain
An experimental formulation of a hydrogel, injected into spinal discs, proved safe and effective in substantially relieving chronic low back pain caused by degenerative disc disease (DDD), according to new research to be presented at the Society of Interventional Radiology Annual Scientific Meeting, in Boston.
5 Questions with Bill Niland, CEO, ReGelTec, Inc.
“5 Questions With…” is a weekly BioBuzz series where we reach out to interesting people in the BioHealth Capital Region to share a little about themselves, their work, and maybe something completely unrelated.
ReGelTec Presents Early Feasibility Study at ASSR Annual Meeting
ReGelTec, Inc., a clinical stage medical device company developing HYDRAFIL™, a percutaneous treatment for chronic low back pain, announced the presentation of Early Feasibility Study (EFS) results by Dr Alfonso Spath at the American Society of Spine Radiology annual meeting that took place February 19-21, 2021.
Presentation of Early Feasibility Study Results
Dr Doug Beall, medical advisor for ReGelTec, presented at the American Society of Spine Radiology annual meeting on Hydrafil’s development history and the preliminary results of the Early Feasibility Study. Dr Alfonso Spath, Prinicipal Investigator, also presented during the meeting’s scientific session.
ReGelTec: Implanting a Solution for Degenerative Disc Disease
By restoring vertebral disc height with an injectable, durable hydrogel, ReGelTec aims to give interventional spine and pain clinicians an effective option for one of the most common causes of low back pain.
ReGelTec, Inc., a Rowan Innovation Venture Fund investment, receives FDA breakthrough designation
ReGelTec, Inc., a medical device company developing a treatment for chronic low back pain, has received breakthrough device designation for its HYRDAFIL System from the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA).